Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC3A2) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine
Функциональная характеристика переносчика растворённых веществ LAT-1 (SLC7A5/SLC3A2) в эндотелиальных клетках капилляров головного мозга человека с использованием быстрого количественного определения внутриклеточного изотопно-меченого L-лейцина методом UPLC-MS/MS
2022-03-26
SCID: 54.1/8eav2x8m
Discuss with AI
JPH203 and BCH inhibitorsLAT-1 (SLC7A5/SLC3A2)UPLC-MS/MSblood–brain barrierisotopically labeled L-leucine
Figures from the paper
Abstract (AI)
The solute carrier L-type amino acid transporter 1 (LAT-1/SLC7A5) is a viable target for drug delivery to the central nervous system (CNS) and tumors due to its high abundance at the blood–brain barrier and in tumor tissue. LAT-1 is only localized on the cell surface as a heterodimer with CD98, which is not required for transporter function. To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ([13C6, 15N]-L-leucine), with a dynamic range of 0.1–1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition capacity of new compounds. The assay was established in a 96-well format, facilitating high-throughput experiments, and, hence, can support the screening for novel inhibitors. Applicable recommendations of the US Food and Drug Administration and European Medicines Agency for bioanalytical method validation were followed to validate the assay. The assay was applied to investigate the IC50 of two well-known LAT-1 inhibitors on hCMEC/D3 cells: the highly specific LAT-1 inhibitor JPH203, which was also used to demonstrate LAT-1 specific uptake, and the general system L inhibitor BCH. In addition, the [13C6, 15N]-L-leucine uptake was determined on two human brain capillary endothelial cell lines (NKIM-6 and hCMEC/D3), which were characterized for their expressional differences of LAT-1 at the protein and mRNA level and the surface amount of CD98. The IC50 values of the inhibitors were in concordance with previously reported values. Furthermore, the [13C6, 15N]-L-leucine uptake was significantly higher in hCMEC/D3 cells compared to NKIM-6 cells, which correlated with higher expression of LAT-1 and a higher surface amount of CD98. Therefore, the UPLC-MS/MS quantification of ([13C6, 15N]-L-leucine is a feasible strategy for the functional characterization of LAT-1 activity in cells or tissue.
Key Findings
1
A validated UPLC-MS/MS assay quantifies intracellular [13C6,15N]-L-leucine over a 0.1–1000 ng/mL dynamic range for functional LAT-1 testing.
2
In hCMEC/D3 cells, LAT-1-specific inhibitor JPH203 and system L inhibitor BCH produced IC50 values concordant with previously reported values.
3
The assay uses a 96-well format, enabling high-throughput evaluation of LAT-1 inhibitors and screening of candidate CNS drug-delivery compounds.
4
The method provides a feasible strategy for quantifying LAT-1-mediated uptake and assessing inhibition capacity in human brain endothelial cells.
5
[13C6,15N]-L-leucine uptake was significantly higher in hCMEC/D3 than NKIM-6 cells, correlating with greater LAT-1 expression and higher surface CD98.
Research Object
LAT-1/CD98 amino acid transporter activity in human brain capillary endothelial cells (hCMEC/D3 and NKIM-6)
Research Subject
LAT-1-mediated intracellular uptake of isotopically labelled L-leucine and its relationship to LAT-1/CD98 expression and inhibition by JPH203 and BCH
Publication Details
Publication Date
2022-03-26
Journal
Publisher
ISSN
Cited by
19
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health2018
The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer2019
L-Type amino acid transporter 1 as a target for drug delivery2020
Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter2021